Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meta Roestenberg

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The Lancet. Infectious Diseases|July 6, 2023
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the NetherlandsJohan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
NPJ Vaccines|January 3, 2024
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trialManon L M Prins, Geert V T Roozen, Cilia R Pothast, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.
Nature Immunology|December 23, 2021
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8<sup>+</sup> T cell responses following COVID-19Anna H E Roukens, Cilia R Pothast, Marion König, et al.
Ebiomedicine|October 14, 2023
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection studyJan Pieter R Koopman, Emma L Houlder, Jacqueline J Janse, et al.
NPJ Vaccines|November 5, 2022
Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liverBlandine Franke-Fayard, Catherin Marin-Mogollon, Fiona J A Geurten, et al.
Nature Medicine|January 3, 2025
Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trialGeert V T Roozen, Roos van Schuijlenburg, Annefleur D O Hensen, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The Lancet. Infectious Diseases|July 6, 2023
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the NetherlandsJohan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
NPJ Vaccines|January 3, 2024
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trialManon L M Prins, Geert V T Roozen, Cilia R Pothast, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.
Nature Immunology|December 23, 2021
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8<sup>+</sup> T cell responses following COVID-19Anna H E Roukens, Cilia R Pothast, Marion König, et al.
Ebiomedicine|October 14, 2023
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection studyJan Pieter R Koopman, Emma L Houlder, Jacqueline J Janse, et al.
NPJ Vaccines|November 5, 2022
Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liverBlandine Franke-Fayard, Catherin Marin-Mogollon, Fiona J A Geurten, et al.
Nature Medicine|January 3, 2025
Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trialGeert V T Roozen, Roos van Schuijlenburg, Annefleur D O Hensen, et al.
Pageof 13